Relevance of in Vitro Leukaemia Cell Survival to Short- and Long Term Clinical Outcome in AML

References

• Hamburger A.W. Use of in vitro tests in predictive cancer chemotherapy. Journal of the National Cancer Institute 1981; 66: 981–988
   PubMed Web of Science ®Google Scholar
• Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science 1977; 197: 461–463
   PubMed Web of Science ®Google Scholar
• Wyllie A.H. Apoptosis (the 1992 Frank Rose Memorial Lecture). British Journal of Cancer 1993; 67: 205–208
   PubMed Web of Science ®Google Scholar
• Korsmeyer S.J. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1993; 80: 879–886
   Web of Science ®Google Scholar
• Hockenbery D., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334–336
   PubMed Web of Science ®Google Scholar
• Reed J.C., Cuddy M., Slabiak T., Croce C.M., Nowell P.C. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 1988; 336: 259–261
   PubMed Web of Science ®Google Scholar
• Kerr J.F.R., Wyllie A.H., Currie A.R. Apoptosis: A basic biological phenomenon with widespread implications in tissue kinetics. British Journal of Cancer 1972; 26: 239–257
   PubMed Web of Science ®Google Scholar
• Miyashita T., Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151–157
   PubMed Web of Science ®Google Scholar
• Weller M., Malipiero U., Aguzzi A., Reed J.C., Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. Journal of Clinical Investigation 1995; 95: 2633–2643
   PubMed Web of Science ®Google Scholar
• Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V.M., Niskanen E., Nordling S., Reed J.C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Research 1995; 55: 4471–4478
   PubMed Web of Science ®Google Scholar
• Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148–3157
   PubMed Web of Science ®Google Scholar
• Campos L., Rouault J.P., Sabido O., Oriol O., Roubi N., Vasselon C., Archimbaud E., Magaud J.P., Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091–3096
   PubMed Web of Science ®Google Scholar
• Löwenberg B., van Putten W.L.J., Touw I.P., Delwel R., Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. New England Journal of Medicine 1993; 93: 614–619
   Web of Science ®Google Scholar
• Hunter A.E., Rogers S.Y., Roberts I.A.G., Barret J., Russell N. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood 1993; 82: 899–903
   PubMed Web of Science ®Google Scholar
• Nørgaard J.M., Langkjer S.T., Palshof T., Clausen N., Pedersen B., Hokland P. Relation of blast cell survival and proliferation to chemotherapy resistance in AML. British Journal of Haematology 1996; 93: 888–897
   PubMed Web of Science ®Google Scholar
• Bennett J.M., Catowsky D., Daniel M.T., Flandrin G., Dalton D.A.G., Gralnick H.R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukaemia. Annals of Internal Medicine 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Bennett J.M., Catowsky D., Daniel M.T., Flandrin G., Dalton D.A.G., Gralnick H.R., Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). British Journal of Haematology 1991; 78: 325–329
   PubMed Web of Science ®Google Scholar
• Ellison R.R., Holland J.F., Weil M., Jacuillat C., Boiron M., Bernard J., Sawitsky A., Rosner F., Gussof B., Silver R.T., Karansas A., Cuttner J., Spurr C.L., Hayes D.M., Blom J., Leone L.A., Haurani F., Kyle R., Hutchison J.L., Jackson Forcier R., Moon J.H. Arabinosyl cytosine: useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507–523
   PubMed Web of Science ®Google Scholar
• Hansen O.P., Pedersen-Bjergaard J., Ellegaard J., Brincker H., Boesen A.M., Christensen B.E., Drivsholm Aa., Hippe E., Jans H., Jensen K.B., Killmann S., Jensen M.K., Karle H., Laursen B., Nielsen J.B., Nissen N.I., Thorling K. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated acute myeloid leukemia: a Danish national phase III trial. Leukemia 1991; 5: 510–516
   PubMed Web of Science ®Google Scholar
• Lie S.O., Jonmundsson G., Mellander L., Siimes M.A., Yssing M., Gustafsson G. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. British Journal of Haematology 1996; 94: 82–88
   PubMed Web of Science ®Google Scholar
• Avanzi G.C., Lista P., Giovinazzo B., Miniero R., Saglio G., Benetton G., Coda R., Cattoretti G., Pegoraro L. Selective growth response to II-3 of a human leukaemic cell line with megakaryoblastic features. British Journal of Haematology 1988; 69: 359–366
   PubMed Web of Science ®Google Scholar
• Huet O., Petit J.M., Ratinaud M.H., Julien R. NADH-dependent dehydrogenase activity estimation by flow cytometric analysis of 3-(4, 5-dimethylthiazolyl-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction. Cytometry 1992; 13: 532–539
   PubMedGoogle Scholar
• Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Medicine 1997; 3: 614–620
   PubMed Web of Science ®Google Scholar
• Yang E., Korsmeyer S.J. Molecular thanatopsis: A discourse on the bcl2 family and cell death. Blood 1996; 88: 386–401
   PubMed Web of Science ®Google Scholar
• Pepper C., Bentley P., Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. British Journal of Haematology 1996; 95: 513–517
   PubMed Web of Science ®Google Scholar